CABOZANTINIB

Brand name:

• Cabometyx®

Pharmaceutical company:

Ipsen Pty Ltd

Condition/indication:
(therapeutic use)

• Hepatocellular carcinoma

PBAC Submission type:

Change to listing (Major)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2019

Related medicines:

--

Submission received for:

July 2019 PBAC meeting

Opportunity for consumer comment:

Open 01/05/2019 and close 12/06/2019 (see PBS Website)

PBAC meeting:

Held on 10/07/2019

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---